Summary
Background
The roles of soluble epoxide hydrolase and lipid mediators in
inflammatory and neuropathic pain could be relevant in laminitis pain
management.
Objectives
To determine soluble epoxide hydrolase (sEH) activity in the digital
laminae, sEH inhibitor potency in vitro, and efficacy of a
sEH inhibitor as an adjunct analgesic therapy in chronic laminitic
horses.
Study design
In vitro experiments and in vivo
case series.
Methods
sEH activity was measured in digital laminae from euthanized healthy
and laminitic horses (n=5–6/group). Potency of seven
synthetic sEH inhibitors was determined in vitro using
equine liver cytosol. One of them (t-TUCB; 0.1 mg/kg bwt IV
every 24 hours) was selected based on potency and stability, and used as
adjunct therapy in 10 horses with severe chronic laminitis (Obel grades 2, 1
horse; 3–4, 9 horses). Daily assessments of forelimb lifts, pain
scores, physiologic and laboratory examinations were performed before
(baseline) and during t-TUCB treatment. Data are presented
as mean±SD and 95% confidence intervals (CI).
Results
sEH activity in the digital laminae from laminitic horses
(0.9±0.6 nmol/min/mg; CI: 0.16–1.55 nmol/min/mg) was
significantly higher (P=0.01) than in healthy horses
(0.17±0.09 nmol/min/mg; CI: 0.07–0.26 nmol/min/mg).
t-TUCB as an adjunct analgesic up to 10 days
(4.3±3 days) in laminitic horses was associated with significant
reduction in forelimb lifts (36 ± 22%; CI:
9–64%) and in pain scores (18±23%; CI:
2–35%) compared to baseline (P=0.04). One horse
developed gas colic and another corneal vascularization in a blind eye
during treatment. No other significant changes were observed.
Main Limitations
Absence of control group and evaluator blinding in case series.
Conclusions
sEH activity is significantly higher in the digital laminae of
actively laminitic compared to healthy horses, and use of a potent inhibitor
of equine sEH as adjunct analgesic therapy appears to decrease signs of
pathologic pain in laminitic horses.